|
May 27
|
Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference
|
|
May 23
|
Genmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025
|
|
May 22
|
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
May 21
|
Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference
|
|
May 14
|
Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress
|
|
May 12
|
Transactions in Connection with Share Buy-back Program
|
|
May 9
|
Genmab AS (GMAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives
|
|
May 8
|
Genmab Announces Financial Results for the First Quarter of 2024
|
|
Feb 13
|
Why Genmab (GMAB) and Sonic Automotive (SAH) Are Advancing Today
|
|
Feb 13
|
Notice to Convene the Annual General Meeting of Genmab A/S
|
|
Feb 13
|
Genmab AS (GMAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...
|
|
Feb 12
|
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
|
|
Feb 12
|
Genmab Publishes 2024 Annual Report
|
|
Jan 23
|
Grant of Restricted Stock Units and Warrants to Employees in Genmab
|
|
Jan 3
|
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference
|